2006 JASN IMPACT FACTOR 7.371	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2005050463v1 16/10/3015    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chapman, J. R. Articles by Nankivell, B. J. Search for Related Content PubMed PubMed Citation Articles by Chapman, J. R. Articles by Nankivell, B. J.

Chronic Renal Allograft Dysfunction

Centre for Transplant and Renal Research, Department of Renal Medicine, Westmead Hospital, University of Sydney, Sydney, Australia

Address correspondence to: Dr. Jeremy R. Chapman, Department of Renal Medicine, Westmead Hospital, Westmead, New South Wales 2145, Australia. Phone: 61-2-9845-6349; Fax: 61-2-9845-8300; E-mail: jeremy_chapman{at}wsahs.nsw.gov.au

The major causes of renal transplant loss are death from vascular, malignant or infectious disease, and loss of the allograft from chronic renal dysfunction associated with the development of graft fibrosis and glomerulosclerosis. Chronic allograft nephropathy (CAN) is the histologic description of the fibrosis, vascular and glomerular damage occurring in renal allografts. Clinical programs rely on monitoring change in serum creatinine for identification of patients at risk of CAN, but this change occurs late in the course of the disease, and underestimates the severity of pathologic change. CAN has several causes: ischemia-reperfusion injury, ineffectively or untreated clinical and subclinical rejection, and superimposed calcineurin inhibitor nephrotoxicity, exacerbating pre-existing donor disease. Once established, interstitial fibrosis and arteriolar hyalinosis lead to progressive glomerulosclerosis over the subsequent years. There have been a number of approaches to treatment aimed at reducing the impact of CAN, mostly centered around avoidance of calcineurin inhibitors through their elimination in all, or just selected, patients. These immunosuppression strategies combine corticosteroids with azathioprine or mycophenolate mofetil, and/or sirolimus and everolimus. Late identification of CAN in individual patients has meant that strategies for intervening to prevent chronic renal allograft dysfunction and subsequent graft loss tend to be "too little and far too late."

This article has been cited by other articles:

				D. Seron, W. Arns, and J. R. Chapman Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies Nephrol. Dial. Transplant., April 2, 2008; (2008) gfn130v1. [Full Text] [PDF]

				S. Chadban New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients? Nephrol. Dial. Transplant., March 8, 2008; (2008) gfn052v1. [Full Text] [PDF]

				H. S. Leong, B. M. Mahesh, J. R. Day, J. D. Smith, A. D. McCormack, G. Ghimire, T. J. Podor, and M. L. Rose Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor J. Leukoc. Biol., February 1, 2008; 83(2): 263 - 271. [Abstract] [Full Text] [PDF]

				B. Mahesh, H.-S. Leong, A. McCormack, P. Sarathchandra, A. Holder, and M. L. Rose Autoantibodies to Vimentin Cause Accelerated Rejection of Cardiac Allografts Am. J. Pathol., April 1, 2007; 170(4): 1415 - 1427. [Abstract] [Full Text] [PDF]

				A. Grenz, T. Eckle, H. Zhang, D. Y. Huang, M. Wehrmann, C. Kohle, K. Unertl, H. Osswald, and H. K. Eltzschig Use of a hanging-weight system for isolated renal artery occlusion during ischemic preconditioning in mice Am J Physiol Renal Physiol, January 1, 2007; 292(1): F475 - F485. [Abstract] [Full Text] [PDF]

				S. C.-W. Tang, K. W. Chan, C. S.-O. Tang, M. F. Lam, C. Y. Leung, K. C. Tse, C. S. Li, Y. W. Ho, M. K.-L. Tong, K. N. Lai, et al. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3243 - 3251. [Abstract] [Full Text] [PDF]

				J. R. Chapman and B. J. Nankivell Nephrotoxicity of ciclosporin A: short-term gain, long-term pain? Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2060 - 2063. [Full Text] [PDF]

				W. Harmon, K. Meyers, J. Ingelfinger, R. McDonald, M. McIntosh, M. Ho, L. Spaneas, J. A. Palmer, M. Hawk, C. Geehan, et al. Safety and Efficacy of a Calcineurin Inhibitor Avoidance Regimen in Pediatric Renal Transplantation J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1735 - 1745. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673